| Case number | Author/year | Age/sex | Site | Diagnosis | Treatment | Outcome |
| 1 | Current case | 78/F | Peritoneal, pleural, | Follicular lymphoma | Bendamustine + rituximab | Resolution | 2 | Arasawa, 2014 [3] | 74/M | Peritoneal | DLBCL | R-CHOP | Resolution | 3 | Jiang, 2013 [4] | 28/M | Peritoneal, pleural | Non-Hodgkin Lymphoma | DOLP + HDAra-C | Resolution | 4 | Yamamoto, 2013 [5] | 87/M | Peritoneal | DLBCL | R-CHOP | Resolution | 5 | Etonyeaku, 2012 [6] | 18/F | Peritoneal, pleural | Burkitt’s lymphoma | MEV | Died due to treatment effects | 6 | Kashyap, 2011 [7] | 21/F | Peritoneal, pleural, pericardial | DLBCL | R-CHOP | Resolution | 7 | Ionnidou-Papagiannaki 2009 [8] | 38/M | Peritoneal, pleural, pericardial | T-cell lymphoma | CHOEP | Died due to GI bleeding | 8 | Gonen, 2007 [9] | 53/M | Peritoneal | Hodgkin lymphoma | ABVD | Regression after two cycles chemotherapy | 9 | Ward, 2008 [10] | Middle age/F | Peritoneal | Follicular lymphoma | Chemotherapy unspecified | Resolution | 10 | Bachmeyer, 2004 [11] | 71/M | Peritoneal | Follicular lymphoma | CHVP + interferon alpha | 50% reduction | 11 | Oosterbosch, 1995 [12] | 68/F | Peritoneal, pleural | DLBCL | CVP | Regression | 12 | Hufford, 1988 [13] | 49/F | Peritoneal | Mixed cellularity (Hodgkin lymphoma) | CVP, doxorubicin followed by CHOP | Resolution | 13 | Hufford. 1988 [13] | 67/F | Peritoneal | Small cleaved cell (NHL) | CVP | No response to chemotherapy, resolution after diuretics | 14 | Hufford, 1988 [13] | 58/M | Peritoneal | Hodgkin lymphoma | MOPP | Resolution | 15 | Hufford, 1988 [13] | 60/M | Peritoneal | Small cleaved cell (NHL) | CHOMP + bleomycin | Resolution |
|
|
R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisolone; CHOMP: cyclophosphamide, doxorubicin, vincristine, and prednisone + bleomycin; MOPP: Mustargen, Oncovin, procarbazine, and prednisone; CHVP: cyclophosphamide, doxorubicin, etoposide, and prednisolone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; CHOEP: cyclophosphamide, hydroxydaunorubicin, Oncovin, etoposide, and prednisone; DOLP: daunorubicin, vincristine, L-asparaginase, and prednisone; HDAra-C: high dose cytarabine; MEV: methotrexate, cyclophosphamide, and vincristine.
|